S.-B. Kim

483 total citations
20 papers, 308 citations indexed

About

S.-B. Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, S.-B. Kim has authored 20 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in S.-B. Kim's work include Cancer Immunotherapy and Biomarkers (5 papers), Esophageal Cancer Research and Treatment (5 papers) and Advanced Breast Cancer Therapies (4 papers). S.-B. Kim is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Esophageal Cancer Research and Treatment (5 papers) and Advanced Breast Cancer Therapies (4 papers). S.-B. Kim collaborates with scholars based in South Korea, United States and Japan. S.-B. Kim's co-authors include Robert S. Elliott, Xavier Pivot, Semiglazov Vf, Bohuslav Melichar, Harald Weber, Carina Hillenbach, B L Lum, Daniil Stroyakovskiy, Christian Jackisch and Cristina Saura and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Japanese Journal of Clinical Oncology.

In The Last Decade

S.-B. Kim

20 papers receiving 302 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S.-B. Kim South Korea	8	222	104	83	58	44	20	308
Laura Faivre France	9	181 0.8×	38 0.4×	158 1.9×	56 1.0×	63 1.4×	16	307
Maria Anderson United States	8	349 1.6×	55 0.5×	115 1.4×	38 0.7×	82 1.9×	10	423
Elías Gracia Cuba	7	156 0.7×	60 0.6×	73 0.9×	13 0.2×	64 1.5×	13	289
Danilo Galizia Italy	10	179 0.8×	22 0.2×	108 1.3×	68 1.2×	58 1.3×	32	285
Mei-Lin Ah-See United Kingdom	9	128 0.6×	116 1.1×	52 0.6×	53 0.9×	40 0.9×	21	243
Catherine Dubos‐Arvis France	8	310 1.4×	104 1.0×	348 4.2×	49 0.8×	57 1.3×	11	476
Wenxiao Jia China	10	219 1.0×	31 0.3×	157 1.9×	88 1.5×	95 2.2×	25	374
Yuanhu Yao China	8	79 0.4×	39 0.4×	67 0.8×	47 0.8×	62 1.4×	25	234
Hongtao Luo China	9	119 0.5×	41 0.4×	140 1.7×	71 1.2×	118 2.7×	54	333
Maria Karina Greece	9	239 1.1×	76 0.7×	92 1.1×	29 0.5×	53 1.2×	12	291

Countries citing papers authored by S.-B. Kim

Since Specialization

Citations

This map shows the geographic impact of S.-B. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.-B. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.-B. Kim more than expected).

Fields of papers citing papers by S.-B. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.-B. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.-B. Kim. The network helps show where S.-B. Kim may publish in the future.

Co-authorship network of co-authors of S.-B. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of S.-B. Kim. A scholar is included among the top collaborators of S.-B. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.-B. Kim. S.-B. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saura, Cristina, Shanu Modi, Ian E. Krop, et al.. (2023). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Annals of Oncology. 35(3). 302–307. 50 indexed citations

Guo, Ye, Myung‐Ju Ahn, Anthony T.�C. Chan, et al.. (2019). Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Annals of Oncology. 30(11). 1831–1839. 40 indexed citations

Kim, S.-B., Toshihiko Doi, Ken Kato, et al.. (2019). KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy. Annals of Oncology. 30. ix42–ix43. 4 indexed citations

Jeong, Jae Ho, Jin‐Hee Ahn, Kyung Hae Jung, et al.. (2019). Leuprorelin (LEUP) combined with Letrozole (LET) with/without everolimus (EVE) in ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550). Annals of Oncology. 30. v107–v107. 1 indexed citations

Emens, Leisha A., Francisco J. Esteva, Mark Beresford, et al.. (2019). Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Annals of Oncology. 30. v104–v104. 47 indexed citations

Jonas, Sarah Flora, Maria Vittoria Dieci, Guillaume Bataillon, et al.. (2019). Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy. Annals of Oncology. 30. v55–v55. 4 indexed citations

Im, Young‐Hyuck, et al.. (2019). Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with advanced breast cancer (ABC): Final results from EVEREXES. Annals of Oncology. 30. ix15–ix15. 1 indexed citations

Kim, S.-B., Bhumsuk Keam, Seong Hoon Shin, et al.. (2019). First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours. Annals of Oncology. 30. v168–v168. 4 indexed citations

Lee, Ki Hoon, Jae Hong Seo, Seok Yun Kang, et al.. (2019). Phase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364). Annals of Oncology. 30. v124–v124. 1 indexed citations

10.

Cho, Byoung Chul, Ken Kato, Masanobu Takahashi, et al.. (2019). Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. Annals of Oncology. 30. v873–v874. 12 indexed citations

11.

Lee, Ki Hoon, S.-B. Kim, Joohyuk Sohn, et al.. (2019). Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA. Annals of Oncology. 30. ix14–ix14. 2 indexed citations

12.

Shen, Lin, Jaffer A. Ajani, S.-B. Kim, et al.. (2018). A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). Annals of Oncology. 29. viii264–viii264. 1 indexed citations

13.

Im, Hyeon-Su, Jeonggyu Kang, Yang Hee Kim, et al.. (2018). The role of comprehensive evaluation for clinical complete response in predicting pathologic complete response in patients treated with neoadjuvant chemoradiation for esophageal squamous cell carcinoma (ESCC). Annals of Oncology. 29. viii213–viii213. 1 indexed citations

14.

Choi, Woo Jung, Hee Jung Shin, Eun Young Chae, et al.. (2017). Long-term Survival Outcomes of Primary Breast Cancer in Women With or Without Preoperative Magnetic Resonance Imaging: A Matched Cohort Study. Clinical Oncology. 29(10). 653–661. 18 indexed citations

15.

Jackisch, Christian, S.-B. Kim, Semiglazov Vf, et al.. (2014). Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Annals of Oncology. 26(2). 320–325. 86 indexed citations

16.

Park, Hyun, Hyo‐Jin Ahn, S.-B. Kim, et al.. (2013). Electrochemical Synthesis of Amorphous Fe-B Alloys for Magnetostrictive Resonant Sensor. ECS Solid State Letters. 3(1). P1–P3. 1 indexed citations

17.

Yoon, Dok Hyun, Geundoo Jang, Jin Hyoung Kim, et al.. (2012). Randomized Phase II Study of Preoperative Concurrent chemoradiotherapy with or without Induction Chemotherapy with S-1 and Oxaliplatin in Patients with Resectable Esophageal Cancer. Annals of Oncology. 23. xi45–xi46. 1 indexed citations

18.

Sohn, Byeong Seok, et al.. (2011). Updated Longitudinal Data on Acute Exacerbation of Chronic Hepatitis B in Patients With Breast Cancer Receiving Anthracycline-based Adjuvant Chemotherapy: Therapeutic vs. Pre-emptive Use of Lamivudine. Japanese Journal of Clinical Oncology. 41(9). 1059–1066. 12 indexed citations

19.

Choi, Yoon‐Seok, Jin‐Hee Ahn, S.-B. Kim, et al.. (2009). Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Annals of Oncology. 20(8). 1337–1343. 18 indexed citations

20.

Ahn, Jin‐Hee, et al.. (2005). Phase II study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Journal of Clinical Oncology. 23(16_suppl). 895–895. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact